Guest View
User: Pass: | become a member
Posts Tagged ‘BMY’

Green Mountain Coffee Call Spread Looks For Shares To Rebound

www.interactivebrokers.com

GMCR – Green Mountain Coffee Roasters, Inc. – Weekly call and put options on Green Mountain Coffee Roasters attracted a mix of bullish and bearish trades today, with shares in the provider of the Keurig single-cup brewing machines down more than 2.0% during the first half of the session at $73.25.

Shares in GMCR have dropped approximately 17% during the past month, but a debit call spread purchased on the stock during the first 30 minutes of the trading week indicates one strategist is positioning for the price of the underlying to rebound during the next four trading sessions. It looks like the trader purchased a 460-lot Oct 04 ’13 $74/$77.5 call spread for a net premium of $1.07 per contract. The spread makes money if shares in GMCR rally 2.5% over the current price of $73.25 to exceed the effective breakeven point at $75.07, and makes maximum potential profits of $2.43 per contract given a roughly 6.0% rally in the price of the underlying to $77.50 by expiration this weekend. 

BMY – Bristol-Myers Squibb Co. – Shares in the drug maker are bucking the trend today, up as much as 0.75% during morning trading to $46.54, amid a down day for U.S. stocks.

Trading in BMY call options today indicates some traders are positioning for shares in the name to rally significantly in the next couple of months. The most active contracts by volume on Bristol-Myers are the Nov $50 strike calls, with around 5,000 lots in play against open interest of just 16 contracts. Time and sales data from this morning suggests most of the volume was purchased at an average premium of $0.29 each. Buyers of the $50 calls stand ready to profit at November expiration in the event that shares rally 8.0% to exceed an average breakeven point and fresh 52-week high of $50.29. Shares in Bristol-Myers traded up to $49.57 in June, the highest level in more than a decade. 


Tags: ,




Busy Day For Bristol-Myers Options As Shares Sprint Higher

www.interactivebrokers.com

Options brief will resume May 20th, 2013.

Today’s tickers: BMY, TIBX & WM

BMY - Bristol-Myers Squibb Co. – Shares in drug maker, Bristol-Myers Squibb Co., are ripping higher today, up 6.5% at $44.94, the highest level in more than a decade, ahead of the release of the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting abstracts tonight. The ASCO Annual Meeting begins on May 31st in Chicago. Options on BMY are far more active than usual today, with overall volume topping 64,000 contracts by 12:25 p.m. ET, versus average daily volume of around 11,400 contracts. Traders appear to be snapping up call options on the name, establishing near-term bullish positions on the stock to position for further gains in the price of the underlying. Front month calls are seeing most of the action, with intraday call volume well in excess of open interest across several striking prices. More than 7,000 calls have traded at the May $45 strike against open interest of 316 contracts, with roughly 3,600 calls purchased during the first half of the session for an average premium of $0.54 each. Call buyers make money if shares in BMY rally another 1.3% over the current level of $44.94 to settle above the average breakeven price of $45.54 by expiration this week. In and out of the money call options expiring June 21st are also seeing heavy volume in today’s session.

TIBX - TIBCO Software, Inc. – Upside call buying on software maker, TIBCO, suggests some traders are positioning for the price of the underlying to continue to gain ground in the near term. The stock is up 0.40% this morning at $20.91 as of 11:40 a.m. ET. Shares in TIBX, down roughly 30% since this time last year, have managed to rise 15% off a two-year low of $18.18 reached back on April 19th. Bullish options are changing hands at the Jun $20 strike today, with around 5,000 calls in play versus open interest of 2,742 contracts. Time and sales data indicates the bulk of…
continue reading


Tags: , ,




Straddle-Strategist Sells Flextronics Options

www.interactivebrokers.com

Today’s tickers: FLEX, BMY, CQB & TSS

FLEX - Flextronics International, Ltd. – The Singapore-based provider of electronics manufacturing services popped up on our scanners after one big player sold a massive straddle in the July contract. Shares in Flextronics are currently up 5.0% at $8.14 as of 11:55am in New York. The sizable straddle play composed of a total of 49,000 FLEX options is almost on par with the overall level of open interest on the stock of 56,483 contracts. It looks like the investor is reeling in time-rich, in-the-money call premium as well as just out-of-the-money put premium, in the expectation that volatility will come off and shares in the name will remain around this level. The straddle-strategist sold 24,500 calls at the July $8.0 strike for a premium of $0.70 each, and sold 24,500 puts at the same strike for a premium of $0.60 apiece. Gross premium pocketed on the transaction amounts to $1.30 per contract. The trader keeps the full premium received on the sale as long as shares in FLEX settle at $8.00 at expiration in July. The short straddle strategy implies the investor at least sees shares trading within a certain range through expiration. In this case, the trader keeps some of the premium received and staves off losses unless shares in FLEX swing above the upper breakeven price of $9.30, or slip beneath the lower breakeven point at $6.70. The short stance in both call and put options expose the trader to potentially devastating losses in the event that shares work against him in the next few months. However, the investor need not hold the position to expiration. The trader may be able to buy back the straddle at an advantageous price at some point, benefiting from the erosion of time value as well as subsiding levels of implied volatility.…
continue reading


Tags: , , ,




Friday Already? What Next?

QQQQ WEEKLYWhat a wild week! 

The Dow is up 400 points since Monday and we are just 150 points away from our November 4th high.  Once we get over 11,500, we have no reason at all to be bearish from a technical standpoint and fundamentals are out the window so what else should we be looking at?  We ended up too bearish on our $10K-$50K Virtual Portfolio as we hit our double-down targets on a couple of index shorts so I am CLEARLY in the bear camp this morning as we’re still playing this as a double-top, rather than a breakout but what if we do break out?  As David Fry said this morning:

Any worries from Europe, China tightening, higher Jobless Claims are mere inconveniences when the light is a bright green.  Let’s face it; this is what the Fed stated they wanted with their POMO activities—higher prices overall with higher stock prices emphasized. The Fed prints money and buys bonds from the Primary Dealers and (wink wink) they know what they’re supposed to do with it. Bears just better get out of the way. 

Looking at David’s Nasdaq chart, we can see that we are back at 2007 highs.  I find this truly amazing as it seems to me things aren’t quite as good in America as we THOUGHT they were in 2007, before we found out that Financial earnings were a scam and before our homes lost 1/3 of their value and when our neighbors used to all have jobs but CNBC is telling us over and over and over and over again how great things are so it must be true because they are on TV and TV doesn’t lie to us.  

So there’s our ridiculous rally premise and we’re "very excited" to go bullish if we break over the 2007 market highs.  XLF has been a real laggard so we like taking advantage of a run in the banks with trade ideas like the FAS April $20/25 bull call spread at $2.70, selling the April $21 puts for $2.55, which is net .15 on the $5 spread that’s already $4.25 in the money.  So, if FAS makes a .75 gain between now and April expiration and holds it, this trade makes a 3,233% profit.  That’s pretty good right?  

See, that’s why we don’t fear the upside.  If
continue reading


Tags: , , , , , , , , ,




Defending Your Virtual Portfolio With Dividends – Q4 (Members Only)

In uncertain markets, dividends can give you a critical investing edge.

As you can see from the chart on the left, just mindlessly investing in dividend-paying stocks can give you more than a 2:1 annual advantage in your investments

Of course, here at PSW, we teach the art of selling options premiums – something that turns virtually any stock into a "dividend" payer.  For example, MSFT is only a small, 2% dividend-payer but a fairly solid cash-machine of a stock that we don’t feel is likely to go bankrupt overnight so it makes for a nice safe staple in a long-term virtual portfolio.  But MSFT is also a very poorly-run company that hasn’t grown in 20 years but we can make it a much more interesting stock by simply selling covered calls.

For example, in our August edition of Dividend Payers,  we looked at MSFT for $24.23 and we sell the Sept $24 calls for .77.  This lowered our effective basis to $23.46 and selling the call putus in no special danger – we simply agreed to sell MSFT for $24 on expiration day in September (the 17th).

The stock was called away from us, and we made a .54 profit or 2.3% of our net $23.46 cash investment in less than 30 days.  That works out to a 26% annualized ROI and we had an opportunity (as we had expected) to buy the stock again and again at $24 on Oct 4th and 5th and sell the November $24 calls for .90 for a net $23.10 re-entry and ANOTHER 3.8% GAIN if we are called away at $24 or greater on Nov 19th.  Doesn’t that beat waiting a whole quarter for your 1% dividend checks?  

Of course, you can optimize all this with timing and we favor stocks that are on sale – this is just a very simple example of how our most basic options strategy can drastically boost your annual returns on any stock in your virtual portfolio.

Let’s say you don’t want to mess around with MSFT every month.  You could have simply sold the 2012 $22.50s for $4.40 (also suggested in the August post), that dropped your net entry from $24.23 to $19.83 and getting called away at $22.50 would be a profit of 13.5% over 17 months PLUS you would be getting your…
continue reading


Tags: , , , , , , , , , , , , , , , , , , , , ,




Bullish Strategist Positions for Rebound in Plains Exploration & Production Co. Shares

www.interactivebrokers.com

Bullish strategist positions for rebound in Plains Exploration & Production Co. shares

Today’s tickers: PXP, MRVL, SRE, RIMM, MU, AFL, BMY & DELL

PXP – Plains Exploration & Production Co. – The implementation of a three-legged bullish options combination play on Plains Exploration & Production Co. drew our attention to the November contract where one investor utilized call and put options to position for a rebound in the price of the underlying stock. Shares of the independent oil and gas company soured in late afternoon trading, slipping 3.2% lower to stand at $20.98 by 3:35 pm (ET). PXP’s current price of $20.98 represents a 40.4% decline in value since April 15, 2010, when the stock touched an intraday high of $35.41. But, the options activity observed in the November contract today indicates one trader is expecting the stock to rebound sharply ahead of expiration in five months time. The investor essentially sold short put options in order to partially finance the purchase of a debit call spread. The trader purchased 10,000 calls at the November $22.5 strike for a premium of $2.45 each, sold 10,000 calls at the higher November $28 strike for a premium of $0.70 each, and finally sold 10,000 puts at the November $17.5 strike for a premium of $1.30 a-pop. The net cost of the transaction amounts to $0.45 per contract. Thus, the investor responsible for the three-legged play is positioned to make money as long as PXP’s shares rally 9.4% to surpass the effective breakeven price of $22.95 by expiration day in November. Maximum potential profits of $5.05 per contract are available to the trader if Plains’ shares surge 33.5% to surpass $28.00 by November expiration.

MRVL – Marvell Technology Group Ltd. – Global semiconductor maker, Marvell Technology Group Ltd., popped up on our ‘most active by options volume’ market scanner in the second half of the trading session due to rampant bearish options activity in the July and August contracts. Marvell’s shares edged 1.50% lower this afternoon to stand at $17.11 just ahead of the closing bell. Pessimistic traders expecting shares to continue lower ahead of July expiration sold 3,100 calls at the July $17 strike for an average premium of $0.74 each. Call selling spread to the August $15 strike where 2,300 in-the-money calls were sold at an average premium of $2.52 per contract. Perhaps in-the-money call sellers are hoping to keep…
continue reading


Tags: , , , , , , ,




Marvell Technology Group Ltd. Call Options Fly Off The Shelves

www.interactivebrokers.com

Today’s tickers: MRVL, EFA, MSFT, PFE, BMY, BAC, GME, NFLX & PM

MRVL – Marvell Technology Group Ltd. – The semiconductor maker popped onto our ‘most active by options volume’ market scanner late in the session due to rampant call buying in the June and July contracts. Marvell’s shares are higher by 1.65% to $17.74 just before 3:30 pm (ET). Near-term optimistic individuals itching for continued appreciation in the price of the underlying stock purchased approximately 9,000 calls at the June $18 strike for an average premium of $0.33 apiece. Investors long the calls make money if Marvell’s shares rally at least 3.325% from the current price of $17.74 to exceed the average breakeven point to the upside at $18.33 by expiration day in one week. Buying interest spread to the July $18 strike where bullish players paid an average premium of $0.89 per contract to take ownership of some 5,100 call options. Traders holding these contracts accumulate profits as long as MRVL’s shares increase 6.5% to surpass the average breakeven price of $18.89 by July expiration.

EFA – iShares MSCI EAFE Index Fund – The implementation of a large-volume short strangle on the EFA, an exchange-traded fund designed to provide investment results that correspond to the price and yield performance of the MSCI EAFE Index – an index which includes stocks from Europe, Australasia and the Far East, indicates one options strategist expects shares of the underlying fund to remain range-bound through September expiration. Shares of the EFA are trading lower by 0.63% to stand at $48.53 with less than 45 minutes remaining before the closing bell. The investor responsible for the strangle sold 16,000 puts at the September $42 strike for an average premium of $1.54 apiece in combination with the sale of the same number of calls at the higher September $52 strike for an average premium of $1.15 each. Gross premium pocketed on the transaction amounts to $2.69 per contract. The strangle-seller keeps the full premium received as long as the fund’s share price trades within the boundaries of the strike prices described through expiration. The short stance assumed in both call and put options expose the responsible party to losses in the event that shares rally above the upper breakeven price of $54.69, or if shares trade beneath the lower breakeven point at $39.31 at expiration. We note that shares of the fund have not…
continue reading


Tags: , , , , , , , ,




Barrage of Bearish Plays Befall Airgas, Inc.

www.interactivebrokers.com

Today’s tickers: ARG, QSFT, VTR, MET, SPWRA, USO, JPM, BMY, ADI & EXPE

ARG – Airgas, Inc. – Options investors initiated diverse bearish strategies on the distributor of industrial, medical and specialty gases this afternoon with shares of the underlying stock lower by 1.75% to $61.73 as of 3:15 pm (ET). Pessimistic players are likely wary of potential sharp share price erosion should Air Products & Chemicals Inc., the industrial gases maker forging a hostile takeover of Airgas in a proposed $5.1 billion bid for the company, fail to ultimately close the deal. Maybe bearish options investors are taking a cue from Paul Huck, CFO at Air Products & Chemicals, who yesterday stated, “there is a large drop in the stock price awaiting this, should Air Products go away” because “If we go away, who else is going to show up and pay this?” Airgas’s share price, which is up roughly 39% since Air Products’ offer went public ahead of February 5, 2010, would likely come crashing down if for some reason Air Products walks away given the lack of other serious competing offers for ARG at this time. Bearish traders bracing for potential share price hemorrhaging purchased a debit put spread and sold calls in the July contract and enacted a ratio bearish risk reversal in the October contract. One investor purchased 2,925 puts at the July $55 strike for a premium of $1.50 each, and sold the same number of puts at the lower July $50 strike for $0.65 apiece. Net premium paid for the spread amounts to $0.85 per contract, thus yielding maximum potential profits of $4.15 each if Airgas shares decline 19% to breach the $50.00 level by expiration day. The sale of 5,000 calls at the July $65 strike for an average premium of $1.05 each may or may not be the work of the same investor. Open interest of 19,000+ calls at the July $65 strike implies the call seller could be closing out a previously established long stance on the stock. Otherwise, the responsible party expects to keep the $1.05 premium per contract received on the sale as long as shares of the underlying stock do not exceed $65.00 ahead of July expiration. Finally, one pessimistic individual populating the October contract sold 5,000 calls at the October $70 strike for a premium of $1.28 each in order to buy twice as many puts…
continue reading


Tags: , , , , , , , , ,




The Calm Before the Storm – Big Pharma Is Gonna Have Big Problems and Pfizer is the BIGGEST

Second coming of the calm before the storm; fear not, there's time to find shelter. - Ilene 

The Calm Before the Storm – Big Pharma Is Gonna Have Big Problems and Pfizer is the BIGGEST

Courtesy of Pharmboy, member of Phil's Stock World 

This is a brief article of where the pharmaceutical industry has been, and where it could be headed in the near future.  In contrast to past articles where I focused on the pipelines of GSK, LLY, MRK, BMY and ‘biotechs’ GENZ, GILD, and others, this is a summary of the industry.  The overall market continues its grind up and I am gun-shy of its continued direction, but with the passage of the health care bill, biotechs that serve niche markets will be well positioned to see a rise both in stock price and potential M&A activity.  In addition, as noted on Friday, March 19th on the laggers/leaders of the past month or so, Telecom and Healthcare were at the bottom of the pile.  For the review of Big Pharma and some biotech picks at the end, generic companies are excluded from most data (Merck KGaA, Mylan, Teva and Watson).

From 2002 to 2009, the top pharmaceutical companies by sales had growth rates greater than 12% (compounded annually).  Unfortunately, this growth is not sustainable and should move towards flat to nominal growth by 2014.  The growth decline will challenge these companies to seek more profitable routes, including licensing and acquisitions.  Picking the right companies based upon the science is at the forefront of good investing.  Not they will all succeed because the science is sound, but understanding the molecule, target, and the disease helps guide smart decisions.  Good management helps as well!

Let's start with a summary of potential acquirers.  Table 1 is a list of the 15 largest pharmaceutical and biotech companies ranked by healthcare revenue.  Some companies (e.g., Bayer and Johnson) have additional revenue which is not included the sales data.  

Table 1. Top 13 Pharma Companies in Sales (2009) 

Rank

Company

Sales ($M)

Based/Headquartered in

1

Pfizer

50,001

US

2

Hoffmann–La Roche

46,300*

Switzerland

3

Merck & Co.

45,930**

US

4

Novartis


continue reading


Tags: , , , , , , , , , , , , , , , , , , ,




PetroBras Bear Braces for Aftershock – Buys Ratio Put Spread

www.interactivebrokers.com

Today’s tickers: PBR, HOG, BMY, FXE, KFT, YHOO, MOS, NTGR, BIDU & DIS

PBR – Petroleo Brasileiro SA ADR – Shares of Brazil’s state-owned oil and natural gas company rose 1.20% to $40.02 this afternoon, adding to the nearly 8% recovery in shares since Friday February 5, 2010, up to an intraday high of $40.25. But, painfully recent memories of the nearly 30% decline in the price per PBR-share from $52.88 on December 1, 2009, to a six-month low of $37.31 on February 8, 2010, have one investor casting doubts that this week’s rebound in shares will last. The investor initiated a ratio put spread to hedge against further share price erosion through February expiration. The trader bought 10,000 puts at the February $39 strike for a premium of $0.50 apiece, and sold 20,000 puts at the lower February $36 strike for a premium of $0.10 each. The net cost of the pessimistic play amounts to $0.30 per contract. Thus, the investor is positioned to amass profits should PBR’s shares slip beneath the breakeven price of $38.70 by expiration day. Maximum potential profits of $2.70 per contract are available to the trader if PetroBras’ share price falls 10% from the current price of $40.02 to reach $36.00 by expiration next Friday.

HOG – Harley-Davidson, Inc. – The motorcycle manufacturer’s shares declined 0.25% to $22.67 today prompting pessimistic options trades in the March contract. Investors purchased put spreads to position for potential share price erosion through expiration next month. Approximately 12,500 puts were picked up at the March $22 strike for an average premium of $1.08 apiece, spread against the sale of 12,500 puts at the lower March $19 strike for a premium of $0.25 each. The debit put spreads cost traders a net $0.83 per contract. Maximum potential profits of $2.17 per contract accumulate for put-spreaders if HOG’s share price plummets more than 16% from the current value of the stock to reach $19.00 by expiration.

BMY – Bristol-Myers Squibb Co. – Pharmaceutical company, Bristol-Myers Squibb, attracted bullish options traders today despite the 1.25% decline in the price of its shares to $23.94. One investor is optimistic that BMY’s shares will rally approximately 9% in the next five months to June expiration. The trader purchased a debit call spread to position for potential bullish movement in the price of the underlying stock. It appears the investor purchased 5,900 calls at…
continue reading


Tags: , , , , , , , , ,




 

Help One Of Our Own PSW Members

"Hello PSW Members –

This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible.  Feel free to contact me directly at jennifersurovy@yahoo.com with any questions.

Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts.  After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.)  Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.

http://www.youcaring.com/medical-fundraiser/help-get-shadowfax-out-from-the-darkness-of-medical-bills-/126743

Thank you for you time!

 
 

Zero Hedge

ECB's Asset Monetization Advisor Says There Will Be No Full-Blown QE

Courtesy of ZeroHedge. View original post here.

Submitted by Tyler Durden.

When two months ago, the ECB announced it would hire Blackrock as an advisor for its "Private QE" ABS and Covered Bond purchase program, many eyebrows were raised, mostly out of cynical curiosity whether the ABS purchased would be those structured by the "advisor" itself. Well, according to today's detailed fresh off the printer, pardon the pun, term sheets on the program, it appears that the eligible securities will be almost exclusively of European origin, so one can probably exclude Blackrock advising the ECB on buying ABS structured by Blackrock itself.

However,...



more from Tyler

Chart School

Is the Stock Market Cheap?

Courtesy of Doug Short.

Here is a new update of a popular market valuation method using the most recent Standard & Poor's "as reported" earnings and earnings estimates and the index monthly averages of daily closes for the past month, which is 1993.23. The ratios in parentheses use the monthly close of 2003.37. For the earnings, see the table below created from Standard & Poor's latest earnings spreadsheet.

● TTM P/E ratio = 18.4 (18.2)
● P/E10 ratio = 26.0 (26.0)

The Valuation Thesis

A standard way to investigate market valuation is to study the historic Price-to-Earnings (P/E) ratio using reported earnings for the trailing twelve months (TTM). Proponents of this approach ignore forward estimates because they are often based on wishful thinking, erroneous assumptions, and analyst bias.

...

more from Chart School

Phil's Favorites

Initial Unemployment Claims Per Millions Workers Reach All Time Record Low

Courtesy of Lee Adler of the Wall Street Examiner

Initial unemployment claims virtually always hit their low for the year in the first week of September, but the September 27 week cracked that low to reach an all time record low in claims per million workers. This is an unsettling fact illustrating just how distorted and overheated the US jobs market is in some sectors. Companies can’t find the workers with the qualifications they need, so they’re not laying off. In the past, such conditions have been the precursor to bear markets in stocks along with economic contractions.

The headline, fictional, seasonally adjusted number for initial unemployment claims came in at 287,000. The consensus guesstimate of  Wall Street economists had been 297,000. There was little reaction in the markets, which may have been more focused on Super Ma...



more from Ilene

Digital Currencies

The Mexican Libertad: The Currency Solution?

Better than a Bitcoin? The Mexican Libertad is a real coin made out of silver or gold whose value is based on the price of silver or gold. It's tangible, like our coins and paper money, but the value is pegged to its weight in previous metal. 

The Mexican Libertad: The Currency Solution?

By Jeff Thomas of The International Man

The Libertad is a Mexican coin that was first issued in 1981 in .999 fine gold and then in silver in 1982. Beginning in 1991, the Libertades became the only coins in the world that were issued in the convenient sizes of 1/20, 1/10, 1/4, 1/2, and 1 ounce—again, in both gold and silver. This made them very practical if they were to be used as currency.

But of course, gold and silver coin...



more from Bitcoin

All About Trends

Mid-Day Update

Reminder: David is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

Option Review

VIX Call Spreads Trade

The CBOE Vix Index topped 17.0 and the highest level since early-August on Monday morning amid declines in U.S. equities to start the trading week. The volatility index is off its earlier highs to trade 5.0% higher on the session at 15.65 as of 11:30 am ET. Options volume on the VIX is hovering near 360,000 contracts, or just more than 50% of the average daily reading of around 660,000 contracts. Calls are far more active than put options, as evidenced by the call/put ratio up above 4.2 in morning trading, perhaps as some traders position for volatility to stick around.

Large call spreads traded on the VIX today caught our attention as one big optio...



more from Caitlin

Sabrient

Sector Detector: Stocks fight off predictable weakness, but expect more downside

Courtesy of Sabrient Systems and Gradient Analytics

Yes, the market showed significant weakness last week for the first time in quite a while. In fact, the Dow Jones Industrial Average moved triple digits each day. But it was all quite predictable, as I suggested in last week's article, and certainly nothing to worry about. Now the market appears to be poised for a modest technical rebound, and longer term, U.S. equities should be in good shape for a year-end rally. However, I still believe more downside is in order before any new highs are challenged. Moreover, market breadth is important for a sustained bull run, so the challenge for investors will be to put together broader bullish conviction, including the small caps.

In this weekly update, I give my view of the current market environment, offer a technical analysis of the S&P 500 chart, re...



more from Sabrient

OpTrader

Swing trading portfolio - week of September 29th, 2014

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Market Shadows

Ebola vs. Us

Ebola vs. Us

By Ilene 

Ebola is spreading too quickly for Ebola-vaccine makers to conduct typical studies of safety and efficacy on experimental vaccines. Instead, vaccines will be tested for basic safety, but then deployed with protocols devised now in order to test for efficacy essentially on the field. Testing has to be expedited because the situation in West Africa gets worse every day while there are no approved vaccines or other treatments.

The chart below is from a paper in the New England Journal of Medicine showing estimates of the virus's trajectory projecting out to November 1, 2014. If current trends continue...



more from Paul

Stock World Weekly

Stock World Weekly

Newsletter writers are available to chat with Members regarding topics presented in SWW, comments are found below each post.

The latest issue of Stock World Weekly is now available. Please sign in with your PSW user name and password. Or simply take a free trial to try out our weekly newsletter. 

...

more from SWW

Promotions

Last Chance! See The 'Google-Like' Trading Algorithm 'Live' TODAY

Traders and Investors,

RSVP NOW to attend a special presentation TODAY at Noon or 9:00 pm ET, where you’ll see a powerful trading algorithm that’s been tested and proven to return phenomenal results on a consistent basis. 

In fact, it has an 82% win rate…

And had you only traded the conservative alerts recommended by the algorithm since inception, you would have experienced portfolio gains of more than 200%!

Register NOW and secure your virtual seat for one of Today’s LIVE presentations.

When you register for the webinar, you’ll also get instant access to following trading videos:

  • Instant access to FOUR Quick-Start Expectancy...


more from Promotions

Pharmboy

Biotechs & Bubbles

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Well PSW Subscribers....I am still here, barely.  From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.

First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices.  Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment.  Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer.  For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...



more from Pharmboy



FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>